Skip to main content
    T

    The Joint Corp (JYNT)

    Official site

    HEALTHCARE • MEDICAL CARE FACILITIES • NASDAQ

    $6.91
    +0.01 (+0.14%)

    Market Cap: $98.15M

    Last updated: Oct 16, 2026 at 1:55 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    62%(24/39)
    Avg Surprise
    -108.16%

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$0.08
    Range$0.03 - $0.12
    3 analysts
    EPS RevisionsNo revisions (7d)
    0
    1
    30d
    EPS Estimate DriftChange to current
    90d ago$0.09-5.9%
    60d ago$0.09-5.9%
    30d ago$0.080.0%
    7d ago$0.080.0%
    Current$0.08
    Revenue Consensus
    $15M
    Range$15M - $15M
    4 analysts
    Period ending Dec 31, 2026
    EPS Consensus$-0.05
    Range$-0.05 - $-0.05
    1 analysts
    Revenue Consensus
    $17M
    Range$16M - $18M
    4 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.05---
    Sep 26EST
    		-$0.08---
    Jun 26
    Reported Aug 6
    		$-0.01N/A-109.09%Miss+83.3%
    Mar 26
    Reported May 7
    		$0.08$0.03+166.67%Beat+366.7%
    Dec 25
    Reported Mar 12
    		$0.06$0.04+50.00%Beat-63.7%
    Sep 25
    Reported Nov 6
    		$0.13$0.02+550.00%Beat+160.0%
    Jun 25
    Reported Aug 7
    		$-0.06$-0.07+14.29%Beat+53.8%
    Mar 25
    Reported May 8
    		$-0.03$-0.00-809.09%Miss-133.3%
    Dec 24
    Reported Mar 13
    		$0.17$0.01+1000.67%Beat+122.0%
    Sep 24
    Reported Nov 7
    		$0.05$-0.01+600.00%Beat+200.0%
    Jun 24
    Reported Aug 8
    		$-0.13$-0.01-1200.00%Miss-1200.0%
    Mar 24
    Reported May 2
    		$0.09$-0.01+1000.00%Beat+400.0%
    Dec 23
    Reported Mar 7
    		$-0.75$0.01-7600.00%Miss-1975.0%
    Sep 23
    Reported Nov 9
    		$-0.05$0.01-600.00%Miss-200.0%
    Jun 23
    Reported Sep 13
    		$-0.01$0.01-200.00%Miss-133.3%
    Mar 23
    Reported May 4
    		$-0.03$-0.01-200.00%Miss-200.0%
    Dec 22
    Reported Mar 9
    		$0.04$0.08-50.00%Miss+300.0%
    Sep 22
    Reported Nov 3
    		$0.05$0.06-16.67%Miss-61.5%
    Jun 22
    Reported Aug 4
    		$0.03$-0.01+400.00%Beat-83.3%
    Mar 22
    Reported May 5
    		$-0.01N/A-125.00%Miss-106.3%
    Dec 21
    Reported Feb 24
    		$0.01N/A-83.33%Miss-98.6%
    Sep 21
    Reported Nov 4
    		$0.13$0.03+333.33%Beat+18.2%
    Jun 21
    Reported Aug 5
    		$0.18$0.06+200.00%Beat+1700.0%
    Mar 21
    Reported May 6
    		$0.16$0.05+220.00%Beat+166.7%
    Dec 20
    Reported Mar 4
    		$0.72$0.14+414.29%Beat+700.0%
    Sep 20
    Reported Nov 5
    		$0.11$-0.01+1200.00%Beat+175.0%
    Jun 20
    Reported Aug 6
    		$0.01N/A+107.69%Beat-66.7%
    Mar 20
    Reported May 7
    		$0.06$0.07-14.29%Miss-14.3%
    Dec 19
    Reported Mar 5
    		$0.09$0.07+28.57%Beat+50.0%
    Sep 19
    Reported Nov 7
    		$0.04$0.03+33.33%Beat+300.0%
    Jun 19
    Reported Aug 8
    		$0.03$0.04-25.00%Miss+200.0%
    Mar 19
    Reported May 9
    		$0.07$0.03+133.33%Beat+333.3%
    Dec 18
    Reported Mar 7
    		$0.06$0.03+100.00%Beat+400.0%
    Sep 18
    Reported Nov 8
    		$0.01$0.01+0.00%Beat+133.3%
    Jun 18
    Reported Aug 9
    		$0.01$-0.01+200.00%Beat+112.5%
    Mar 18
    Reported May 10
    		$-0.03$-0.02-50.00%Miss+76.9%
    Dec 17
    Reported Mar 8
    		$-0.02$-0.03+33.33%Beat+88.9%
    Sep 17
    Reported Nov 9
    		$-0.03N/A+57.14%Beat-
    Jun 17
    Reported Aug 10
    		$-0.08$-0.10+20.00%Beat-
    Mar 17
    Reported May 11
    		$-0.13$-0.12-8.33%Miss-
    Dec 16
    Reported Mar 9
    		$-0.18$-0.20+10.00%Beat-

    Key Metrics

    Valuation
    P/E Ratio26.58EV/EBITDA19.82x
    Price/FCF23.28xFCF Yield4.30%
    Profitability
    Profit Margin6.49%Operating Margin3.25%
    ROE10.60%ROICN/A
    Financial Health
    Debt/Equity0.00xInterest CoverageN/A
    Current Ratio1.83xQuick Ratio1.83x
    Trading Statistics
    Beta1.09Avg Volume91.92K
    52-Week High$10.6752-Week Low$6.80

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$7.07
    SMA 20$7.58
    SMA 50$8.05
    SMA 200$8.70
    EMA 10$7.13
    EMA 20$7.43
    EMA 50$7.90
    EMA 200$8.61

    MACD

    Line: -0.37Signal: -0.32Hist: -0.05

    ADX

    ADX: 30.9+DI: 8.1-DI: 25.6

    Aroon & PSAR

    Aroon Up24.0
    Aroon Down96.0
    PSAR$7.16

    Bollinger Bands

    Upper Band$8.78
    Lower Band$6.38
    %B Position3171%(Upper)
    Band Width0.22

    RSI (14-Day)

    Oversold
    25.3

    Momentum Oscillators

    Stoch %K8.4
    Stoch %D6.7
    Williams %R-92.5
    ROC (10d)-7.5%
    Momentum-0.56
    CCI (20d)-82.0
    MFI (14d)10.5

    Volatility Measures

    ATR (14d)$0.25(3.6%)
    StdDev (20d)0.60
    Hist Vol24.0%(Moderate)

    Volume Flow

    VWAP$6.93
    OBV-2.0M
    AD Line-1.6M
    CMF (20d)-0.159

    Volume Metrics

    Avg Vol (20d)92.6K
    Vol Ratio0.7x
    VWMA (20d)$7.66

    Pivot Points

    R3$7.28
    R2$7.16
    R1$7.03
    Pivot Point$6.91
    S1$6.78
    S2$6.66
    S3$6.53

    Advanced Oscillators

    TSI-43.70
    Ultimate Osc45.1
    KST-138.61

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$15.18M$14.82M$15.17M$13.38M$13.27M$13.08M$14.71M$12.65M$12.61M$12.18M$-40,104,476$29.47M
    Cost of Revenue$2.48M$2.72M$2.82M$2.66M$2.77M$2.97M$3.18M$2.81M$2.81M$2.70M$2.81M$2.60M
    Gross Profit$12.70M$12.10M$12.35M$10.72M$10.50M$10.11M$11.53M$9.84M$9.80M$9.48M$-42,910,824$26.87M
    Operating Expenses$13.07M$11.22M$11.61M$10.56M$11.64M$10.78M$10.72M$10.33M$11.58M$9.91M$-45,089,364$27.77M
    R&D$0$0$0$0$0$0$0$0$0$0$0$0
    SG&A$7.56M$7.08M$7.68M$7.30M$7.75M$6.91M$7.51M$7.48M$7.79M$7.34M$-33,924,407$20.21M
    Operating Income$-368,657$873,668$742,410$160,915$-1,138,167$-678,534$809,716$-492,820$-1,779,325$-426,596$2.24M$-898,047
    Interest Income$0$0$0$0$0$0$0$0$0$0$0$0
    Interest Expense$0$0$0$0$0$0$0$0$0$0$3.77M$6,244
    Income Before Tax$-242,219$1.11M$940,642$300,716$-978,245$-492,617$889,445$-408,992$-1,698,854$-390,337$-1,528,682$-904,291
    Income Tax Expense$9,108$11,112$3,513$10,346$11,390$13,404$-19,536$5,391$11,169$8,582$10.53M$-188,018
    Net Income$653,021$1.30M$991,097$855,009$93,363$967,796$17,665$-3,165,139$-3,596,398$946,979$-11,041,599$-716,273
    EBITDA$182,333$1.52M$1.38M$763,762$-558,831$-104,301$1.44M$830,242$-175,042$1.01M$159,992$1.44M
    EBIT$-242,219$1.11M$940,642$300,716$-978,245$-492,617$889,445$-408,992$-1,698,854$-390,337$-1,528,682$-904,291
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about JYNT

    News

    The Joint reacquires Texas rights: what it means for The Joint stock

    The Joint Corp. (JYNT) reacquired regional developer rights across Texas on October 6, 2026, opening potential for over 150 additional clinics and giving the company greater direct control over franchise development....

    ad-hoc-news.de•10/16/26•Bullish

    Joint Q2 2026 Earnings Call Transcript

    Joint (NASDAQ: JYNT) reported significant financial improvements in Q2 2026, including a $560,000 year-over-year increase in consolidated net income and a $1.4 million rise in adjusted EBITDA from continuing operations...

    Benzinga•10/13/26•Bullish

    Discipline and Rules-Based Execution in JYNT Response

    This article provides an analysis of The Joint Corp. (NASDAQ: JYNT) with a focus on sentiment, price positioning...

    Stock Traders Daily•10/12/26•Somewhat-Bearish

    The Joint stock fell 1.04 percent as Texas rights reshape growth

    The Joint stock (JYNT) fell 1.04 percent to USD 7.11 on Nasdaq after the company announced it regained Texas development rights for over 150 clinic opportunities...

    AD HOC NEWS•10/7/26•Neutral

    The Joint Chiropractic Expands Growth Opportunities Through Strategic Territory Reacquisition

    The Joint Corp. announced the reacquisition of regional developer rights in Texas, including major metropolitan areas, as well as other territories such as Chicago, Minnesota, Ohio, Iowa...

    Franchising.com•10/6/26•Bullish

    JYNT Valuation and Fair Value

    P/E
    26.6x
    Forward P/E
    11.9x
    EV/EBITDA
    19.8x
    P/FCF
    23.3x
    PEG
    8.8x
    P/B
    6.2x
    See GNG's fair value

    JYNT Profitability: Margins, ROIC and FCF

    Gross margin
    81.8%
    Operating margin
    3.3%
    Net margin
    6.5%
    ROE
    10.6%
    FCF margin
    7.2%
    FCF yield
    4.3%

    JYNT Competitors

    CompanyTicker
    Humacyte IncHUMA
    PolyPidPYPD
    Corbus Pharmaceuticals HoldingCRBP
    Coya Therapeutics, Inc. Common StockCOYA
    Inovio Pharmaceuticals IncINO
    ImmuCell CorporationICCC
    Unicycive Therapeutics IncUNCY
    Milestone Pharmaceuticals IncMIST

    Sector: Healthcare

    JYNT Analyst Ratings

    Consensus
    Hold
    Analysts
    4
    Strong Buy
    0
    Buy
    1
    Hold
    3
    Sell
    0
    Strong Sell
    0

    JYNT Bull Case vs Bear Case

    Bull case

    • JYNT beat EPS estimates in 75.0% of its last 8 reported quarters.
    • JYNT grew quarterly revenue 14.4% year over year.

    JYNT Earnings: Beat Rate and Next Report

    Beat rate
    6 of 8 quarters (75.0%)
    Average surprise
    182.9%
    EPS estimate (fiscal period ending Sep 30, 2026)
    $0.08
    Estimate revisions (30 days, fiscal period ending Sep 30, 2026)
    0 up, 1 down

    Frequently Asked Questions About JYNT

    Does JYNT pay dividends?

    The Joint Corp (JYNT) does not currently pay a regular dividend.

    What is JYNT's P/E ratio?

    The Joint Corp has a price-to-earnings (P/E) ratio of 26.58.

    What is JYNT's market cap?

    The Joint Corp (JYNT) has a market capitalization of $98.15M with a current stock price of $6.91.

    Related stocks

    Sector: Healthcare

    All stocks starting with J

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In